Post-marketing studies of drug efficacy: why?

[1]  H. Wiedemann,et al.  Drug usage and fetal development: preliminary evaluations of a prospective investigation. , 1972, Advances in experimental medicine and biology.

[2]  J. Joossens,et al.  Moderate sodium restriction and diuretics in the treatment of hypertension. , 1973, American heart journal.

[3]  O. Miettinen,et al.  Postmarketing studies of drug efficacy: When must they be randomized? , 1983, Clinical pharmacology and therapeutics.

[4]  A. Walker,et al.  Postmarketing follow-up. , 1979, JAMA.

[5]  B. A. Barron,et al.  The evaluation of new drugs. Current Food and drug Administration regulations and statistical aspects of clinical trials. , 1967, Archives of internal medicine.

[6]  D. Cherkin,et al.  The use of drugs for unlabeled indications. , 1980, JAMA.

[7]  E. Vesell.  Sounding board. Why are toxic reactions to drugs so often undetected initially? , 1980, New England Journal of Medicine.

[8]  H. Jick.  The discovery of drug-induced illness. , 1977, The New England journal of medicine.

[9]  P. Hoeprich,et al.  Gentamicin therapy in renal failure: a nomogram for dosage. , 1972, Annals of internal medicine.

[10]  K. Nguyen,et al.  Effect of dosage regimen on natriuretic response to furosemide , 1975, Clinical pharmacology and therapeutics.

[11]  W. Wardell,et al.  Postmarketing Surveillance of New Drugs: I. Review of Objectives and Methodology , 1979, Journal of clinical pharmacology.

[12]  Hollister Le.  Tricyclic antidepressants (first of two parts). , 1978 .

[13]  A. Feinstein,et al.  Improved observational method for studying therapeutic efficacy. Suggestive evidence that lidocaine prophylaxis prevents death in acute myocardial infarction. , 1981, JAMA.

[14]  R. Cipolle,et al.  Rapid Gentamicin Elimination in Obstetric Patients , 1980, Obstetrics and gynecology.

[15]  Webster Dc,et al.  Bronchodilator therapy (second of two parts). , 1977 .

[16]  R. Bressler,et al.  Clinical Pharmacology of Oral Antidiabetic Agents , 1977 .

[17]  N. Weiss,et al.  Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. , 1980, The New England journal of medicine.

[18]  O. Miettinen.  The need for randomization in the study of intended effects. , 1983, Statistics in medicine.

[19]  S. Shapiro,et al.  Drug evaluation after marketing. , 1979, Annals of internal medicine.

[20]  P. Doering,et al.  The extent and character of drug consumption during pregnancy. , 1978, JAMA.

[21]  Cohen Sn.  Ethical and legal issues in pediatric drug research. , 1980 .

[22]  A. Feinstein,et al.  The application of therapeutic-trial principles to improve the design of epidemiologic research: a case-control study suggesting that anticoagulants reduce mortality in patients with myocardial infarction. , 1981, Journal of chronic diseases.

[23]  L. Goodwin,et al.  The Evaluation of New Drugs , 1958, The Journal of pharmacy and pharmacology.

[24]  A. Smith,et al.  Incidence of ampicillin-resistant Hemophilus influenzae in otitis media. , 1976, The Journal of pediatrics.

[25]  T. Hutchinson,et al.  POST-MENOPAUSAL ŒSTROGENS PROTECT AGAINST FRACTURES OF HIP AND DISTAL RADIUS A Case-control Study , 1979, The Lancet.

[26]  R. Schwartz,et al.  The increasing incidence of Ampicillin-resistant Haemophilus influenzae. A cause of otitis media. , 1978, JAMA.

[27]  B. Strom,et al.  Can postmarketing surveillance help to effect optimal drug therapy? , 1979, JAMA.

[28]  Finkel Mj.  Drug studies in children. , 1980 .

[29]  E. Reali,et al.  Diazepam elimination in premature and full term infants, and children , 1973, Journal of perinatal medicine.

[30]  R. E. Johnson,et al.  The risk of hip fracture in postmenopausal females with or without estrogen drug exposure. , 1981, American journal of public health.